COVID-19 and sickle cell disease in Bahrain

INTRODUCTION: Coronavirus disease 2019 (COVID-19) is caused by a newly identified strain of the coronavirus family that has been shown to affect the hemoglobin beta chain, the same chain that has sickle cell disease (SCD) mutation. This study was undertaken to see if COVID-19 infection increased dis...

Descripción completa

Detalles Bibliográficos
Autores principales: AbdulRahman, Abdulkarim, AlAli, Salman, Yaghi, Omar, Shabaan, Mohammed, Otoom, Sameer, Atkin, Stephen L., AlQahtani, Manaf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2020
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833176/
https://www.ncbi.nlm.nih.gov/pubmed/32980556
http://dx.doi.org/10.1016/j.ijid.2020.09.1433
_version_ 1783642006111649792
author AbdulRahman, Abdulkarim
AlAli, Salman
Yaghi, Omar
Shabaan, Mohammed
Otoom, Sameer
Atkin, Stephen L.
AlQahtani, Manaf
author_facet AbdulRahman, Abdulkarim
AlAli, Salman
Yaghi, Omar
Shabaan, Mohammed
Otoom, Sameer
Atkin, Stephen L.
AlQahtani, Manaf
author_sort AbdulRahman, Abdulkarim
collection PubMed
description INTRODUCTION: Coronavirus disease 2019 (COVID-19) is caused by a newly identified strain of the coronavirus family that has been shown to affect the hemoglobin beta chain, the same chain that has sickle cell disease (SCD) mutation. This study was undertaken to see if COVID-19 infection increased disease severity in patients with SCD. METHODS: Mass screening of the Bahraini population was undertaken between February and April 2020. RESULTS: A total of 38,092 Bahraini people were tested for COVID-19 during this period; 378 (1%) were SCD patients. Six patients with SCD had COVID-19 (1.6%): three remained asymptomatic, two had mild symptoms and one required oxygen therapy. The SCD patients had a similar average length of stay when compared with non-SCD COVID-19 patients (10.7 days). CONCLUSION: The infection rate, clinical course and viral clearance seen for the SCD patients with COVID-19 were no different to those without SCD.
format Online
Article
Text
id pubmed-7833176
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
record_format MEDLINE/PubMed
spelling pubmed-78331762021-01-26 COVID-19 and sickle cell disease in Bahrain AbdulRahman, Abdulkarim AlAli, Salman Yaghi, Omar Shabaan, Mohammed Otoom, Sameer Atkin, Stephen L. AlQahtani, Manaf Int J Infect Dis Short Communication INTRODUCTION: Coronavirus disease 2019 (COVID-19) is caused by a newly identified strain of the coronavirus family that has been shown to affect the hemoglobin beta chain, the same chain that has sickle cell disease (SCD) mutation. This study was undertaken to see if COVID-19 infection increased disease severity in patients with SCD. METHODS: Mass screening of the Bahraini population was undertaken between February and April 2020. RESULTS: A total of 38,092 Bahraini people were tested for COVID-19 during this period; 378 (1%) were SCD patients. Six patients with SCD had COVID-19 (1.6%): three remained asymptomatic, two had mild symptoms and one required oxygen therapy. The SCD patients had a similar average length of stay when compared with non-SCD COVID-19 patients (10.7 days). CONCLUSION: The infection rate, clinical course and viral clearance seen for the SCD patients with COVID-19 were no different to those without SCD. The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2020-12 2020-09-24 /pmc/articles/PMC7833176/ /pubmed/32980556 http://dx.doi.org/10.1016/j.ijid.2020.09.1433 Text en © 2020 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Short Communication
AbdulRahman, Abdulkarim
AlAli, Salman
Yaghi, Omar
Shabaan, Mohammed
Otoom, Sameer
Atkin, Stephen L.
AlQahtani, Manaf
COVID-19 and sickle cell disease in Bahrain
title COVID-19 and sickle cell disease in Bahrain
title_full COVID-19 and sickle cell disease in Bahrain
title_fullStr COVID-19 and sickle cell disease in Bahrain
title_full_unstemmed COVID-19 and sickle cell disease in Bahrain
title_short COVID-19 and sickle cell disease in Bahrain
title_sort covid-19 and sickle cell disease in bahrain
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833176/
https://www.ncbi.nlm.nih.gov/pubmed/32980556
http://dx.doi.org/10.1016/j.ijid.2020.09.1433
work_keys_str_mv AT abdulrahmanabdulkarim covid19andsicklecelldiseaseinbahrain
AT alalisalman covid19andsicklecelldiseaseinbahrain
AT yaghiomar covid19andsicklecelldiseaseinbahrain
AT shabaanmohammed covid19andsicklecelldiseaseinbahrain
AT otoomsameer covid19andsicklecelldiseaseinbahrain
AT atkinstephenl covid19andsicklecelldiseaseinbahrain
AT alqahtanimanaf covid19andsicklecelldiseaseinbahrain

Ejemplares similares